関連レポート

子宮鏡の世界市場：2031年予測

出版元：Transparency Market Research  出版元について

発行年：2024年1月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 212ページになります。

商品コード：TMR202

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

ヒトパピローマウイルスワクチン(HPV)の世界市場規模は2022年で40億ドル、2031年に91億ドル、市場の平均年成長率は9.4%にて増加する見込みです。

当レポートでは、ヒトパピローマウイルスワクチン(HPV)の市場予測-2031年、各種セグメント別市場分析(価数別、適応症別、国地域別、等)、市場ダイナミクス、パイプライン分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。


【レポート構成概要】
■ヒトパピローマウイルスワクチン(HPV)の世界市場予測2017-2031年
・市場規模(US$)

■価数別、市場-2031年
・2価
・4価、9価
※(市場規模US$)　

■適応症別、市場-2031年
・子宮頸がん
・肛門がん
・膣がん
・陰茎がん
・外陰がん
・口腔咽頭がん
・性器イボ
・その他
※(市場規模US$)

■流通チャネル別、市場-2031年
・医師
・卸売業者
・医師向け販売業者
・政府機関
・官民アライアンス
※(市場規模US$)　

■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
・市場ダイナミクス
・パイプライン分析
・市場シェア分析
・競合状況

■ヒトパピローマウイルスワクチン(HPV)の主要企業プロフィール動向
Merck & Co., Inc.
GlaxoSmithKline plc
Sanofi
AstraZeneca
Serum Institute of India Pvt. Ltd.
Xiame Innovax Biotech CO., LTD.
General Incorporated Foundation
Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
Bharat Biotech

（全212頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Papillomavirus Vaccine Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Human Papillomavirus Vaccine Market Analysis and Forecast, 2017–2031

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Valence
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Valence, 2017–2031
6.3.1. Bivalent
6.3.2. Quadrivalent and Nonavalent
6.4. Market Attractiveness Analysis, by Valence

7. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Cervical Cancer
7.3.2. Anal Cancer
7.3.3. Vaginal Cancer
7.3.4. Penile Cancer
7.3.5. Vulvar Cancer
7.3.6. Oropharyngeal Cancer
7.3.7. Genital Warts
7.3.8. Others
7.4. Market Attractiveness Analysis, by Indication

8. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Physicians
8.3.2. Wholesalers
8.3.3. Physician Distributors
8.3.4. Government Entities
8.3.5. Public and Private Alliances
8.4. Market Attractiveness Analysis, by Indication

9. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Human Papillomavirus Vaccine Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Valence, 2017–2031
10.3.1. Bivalent
10.3.2. Quadrivalent and Nonavalent
10.4. Market Value Forecast, by Indication, 2017–2031
10.4.1. Cervical Cancer
10.4.2. Anal Cancer
10.4.3. Vaginal Cancer
10.4.4. Penile Cancer
10.4.5. Vulvar Cancer
10.4.6. Oropharyngeal Cancer
10.4.7. Genital Warts
10.4.8. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Physicians
10.5.2. Wholesalers
10.5.3. Physician Distributors
10.5.4. Government Entities
10.5.5. Public and Private Alliances
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Valence
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Human Papillomavirus Vaccine Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Valence, 2017–2031
11.3.1. Bivalent
11.3.2. Quadrivalent and Nonavalent
11.4. Market Value Forecast, by Indication, 2017–2031
11.4.1. Cervical Cancer
11.4.2. Anal Cancer
11.4.3. Vaginal Cancer
11.4.4. Penile Cancer
11.4.5. Vulvar Cancer
11.4.6. Oropharyngeal Cancer
11.4.7. Genital Warts
11.4.8. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Physicians
11.5.2. Wholesalers
11.5.3. Physician Distributors
11.5.4. Government Entities
11.5.5. Public and Private Alliances
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Valence
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region

12. Asia Pacific Human Papillomavirus Vaccine Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Valence, 2017–2031
12.3.1. Bivalent
12.3.2. Quadrivalent and Nonavalent
12.4. Market Value Forecast, by Indication, 2017–2031
12.4.1. Cervical Cancer
12.4.2. Anal Cancer
12.4.3. Vaginal Cancer
12.4.4. Penile Cancer
12.4.5. Vulvar Cancer
12.4.6. Oropharyngeal Cancer
12.4.7. Genital Warts
12.4.8. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Physicians
12.5.2. Wholesalers
12.5.3. Physician Distributors
12.5.4. Government Entities
12.5.5. Public and Private Alliances
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Valence
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region

13. Latin America Human Papillomavirus Vaccine Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Valence, 2017–2031
13.3.1. Bivalent
13.3.2. Quadrivalent and Nonavalent
13.4. Market Value Forecast, by Indication, 2017–2031
13.4.1. Cervical Cancer
13.4.2. Anal Cancer
13.4.3. Vaginal Cancer
13.4.4. Penile Cancer
13.4.5. Vulvar Cancer
13.4.6. Oropharyngeal Cancer
13.4.7. Genital Warts
13.4.8. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Physicians
13.5.2. Wholesalers
13.5.3. Physician Distributors
13.5.4. Government Entities
13.5.5. Public and Private Alliances
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Valence
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region

14. Middle East & Africa Human Papillomavirus Vaccine Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Valence, 2017–2031
14.3.1. Bivalent
14.3.2. Quadrivalent and Nonavalent
14.4. Market Value Forecast, by Indication, 2017–2031
14.4.1. Cervical Cancer
14.4.2. Anal Cancer
14.4.3. Vaginal Cancer
14.4.4. Penile Cancer
14.4.5. Vulvar Cancer
14.4.6. Oropharyngeal Cancer
14.4.7. Genital Warts
14.4.8. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Physicians
14.5.2. Wholesalers
14.5.3. Physician Distributors
14.5.4. Government Entities
14.5.5. Public and Private Alliances
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Valence
14.7.2. By Indication
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Merck & Co., Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. GlaxoSmithKline plc
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. AstraZeneca
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Serum Institute of India Pvt. Ltd.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Xiame Innovax Biotech Co., Ltd.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. General Incorporated Foundation
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Bharat Biotechare
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview


List of Tables

Table 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

Table 02: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 03: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

Table 07: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 08: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

Table 11: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

Table 15: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 16: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

Table 19: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 20: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

Table 23: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 24: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031

Figure 02: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Valence, 2022

Figure 03: Global Human Papillomavirus Vaccine Market Value Share, by Valence, 2022

Figure 04: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Indication, 2022

Figure 05: Global Human Papillomavirus Vaccine Market Value Share, by Indication, 2022

Figure 06: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 07: Global Human Papillomavirus Vaccine Market Value Share, by Distribution Channel, 2022

Figure 08: Global Human Papillomavirus Vaccine Market Value Share, by Region, 2022

Figure 09: Global Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

Figure 11: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031

Figure 12: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

Figure 13: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031

Figure 14: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 15: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 16: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Region, 2017 and 2031

Figure 17: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Region, 2023-2031

Figure 18: North America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Country, 2017 and 2031

Figure 21: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

Figure 22: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

Figure 23: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 24: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

Figure 25: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031

Figure 26: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 27: Europe Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 30: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

Figure 31: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

Figure 32: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 33: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

Figure 34: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031

Figure 35: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 36: Asia Pacific Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 39: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

Figure 40: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

Figure 41: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 42: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

Figure 43: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031

Figure 44: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 45: Latin America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 48: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

Figure 49: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

Figure 50: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 51: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

Figure 52: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031

Figure 53: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 54: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 57: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

Figure 58: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

Figure 59: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 60: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

Figure 61: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2022–2031

Figure 62: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

△ 一番上に戻る